AU2015252337B2

AU2015252337B2 - Sunscreen having reduced tendency to stain textiles I

Info

Publication number: AU2015252337B2
Application number: AU2015252337A
Authority: AU
Inventors: Andreas Bleckmann; Kathrin BORCHERS; Tatjana Schade; Katrin Weinert
Original assignee: Beiersdorf AG
Current assignee: Beiersdorf AG
Priority date: 2014-04-28
Filing date: 2015-04-10
Publication date: 2020-07-23
Anticipated expiration: 2035-04-10
Also published as: BR112016025089B1; EP3137041B1; ES2768711T5; DE102014207919A1; CN106255488A; EP3137041A1; ES2768711T3; BR112016025089A2; AU2015252337A1; EP3137041B2; WO2015165711A1

Abstract

The invention relates to a cosmetic preparation containing a) 2,4-bis{[4-(2-ethyl-hexyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine (INCI: bis-ethylhexyloxyphenol methoxyphenyl triazine), and b) one or more complexing agents selected from the group comprising phosphonic acids, phosphoric acids and carboxylic acids with less than 2 nitrogen atoms and/or the alkali salts and/or the amine N-oxides thereof.

Description

Beiersdorf Aktiengesellschaft Hamburg Description

Sunscreen having reduced tendency to stain textiles I

The present invention relates to a cosmetic preparation comprising 2,4-bis{[4-(2 ethylhexyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine (INCI: Bis Ethylhexyloxyphenol Methoxyphenyl Triazine) and one or more complexing agents selected from the group comprising phosphonic acids, phosphoric acids and carboxylic acids having less than 2 nitrogen atoms and/or alkali metal salts thereof and/or amine-N-oxides thereof.

The trend away from pale complexion towards "healthy, athletic tanned skin" has continued for many years. To achieve this, people expose their skin to solar radiation since this causes pigment formation in terms of melanin formation. However, the ultraviolet radiation of sunlight also has a harmful effect on skin. In addition to acute damage (sunburn), long-term harm such as an increased risk of skin cancer arises on excessive irradiation with light in the UVB range (wavelength: 280-320 nm). Excessive exposure to UVB and UVA radiation (wavelength: 320-400 nm) additionally leads to a weakening of the elastic and collagen fibers of the connective tissue. This leads to numerous phototoxic and photoallergic reactions and results in premature ageing of the skin.

To protect the skin, a series of photoprotective filter substances were therefore developed which may be used in cosmetic preparations. In the majority of industrialized countries, these UVA and UVB filters are compiled in the form of positive lists, such as annex 7 to the cosmetics regulation.

The plethora of commercially available sunscreens should not however obscure the fact that these preparations from the prior art have a series of disadvantages.

Cosmetic preparations, such as sunscreen preparations which are applied to the skin, regularly come into contact (intentionally or unintentionally) with clothing and linen (e.g. towels) to which they remain partly adhered (e.g. by "abrasion" or because they are "absorbed" by the fibrous material). In this manner, depending on the type of ingredients, stains and discolorations are formed, especially on light-coloured textiles. These discolorations are particularly caused by non-water-soluble UVA and broadband filters. The stains are difficult to remove by conventional detergents and reinforced even more during the washing process by interactions with ions in the washing water.

Although W02011/101250 is known to those skilled in the art, this document could not have indicated the approach of the present invention.

WO 2012078961 describes chelating polymers for photostabilization of avobenzone and reduction of the formation of colored complexes when washing in hard water, but this document likewise could not have indicated the approach of the present invention. Moreover, a person skilled in the art is aware in principle of cosmetic preparations comprising 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine (INCI: Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine) and the complexing agent EDTA. However, the effect of stain reduction by EDTA is limited in an alkaline medium such as in washing water.

Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.

The object of the present invention, therefore, was to overcome one or more disadvantages of the prior art and in some embodiment to develop a cosmetic preparation (especially a sunscreen) comprising a non-water-soluble broadband filter, such as Bis Ethylhexyloxyphenol Methoxyphenyl Triazine, which can be more easily washed out of textiles contaminated with the preparation.

According to a first aspect the invention provides a cosmetic preparation comprising a) 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine (INCI: Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine);and b) one or more complexing agents selected from the group consisting of - 1-hydroxyethane-(1,1-diphosphonic acid)/ HEDP - aminotrimethylenephosphonic acid/ ATMP - diethylenetriaminepenta(methylenephosphonic acid)/ DTPMP - phosphonobutanetricarboxylic acid/ PBTC - tetrasodium pyrophosphate and/or alkali metal salts thereof .

Unless the context clearly requires otherwise, throughout the description and the claims, the words "comprise", "comprising", and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say, in the sense of "including, but not limited to".

According to a second aspect the invention provides a method for facilitating the ability of cosmetic preparations comprising a) 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(4 methoxyphenyl)-1,3,5-triazine (INCI: Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine) to be washed out from textiles, wherein one or more complexing agents from the group consisting of: - 1-hydroxyethane-(1,1-diphosphonic acid)/ HEDP - aminotrimethylenephosphonic acid/ ATMP - diethylenetriaminepenta(methylenephosphonic acid)/ DTPMP - phosphonobutanetricarboxylic acid/ PBTC - tetrasodium pyrophosphate and/or alkali metal salts thereof, are added to the cosmetic.

According to a third aspect the invention provides the use of a complexing agent from the group from the group consisting of: - 1-hydroxyethane-(1,1-diphosphonic acid)/ HEDP - aminotrimethylenephosphonic acid/ ATMP - diethylenetriaminepenta(methylenephosphonic acid)/ DTPMP - phosphonobutanetricarboxylic acid/ PBTC - tetrasodium pyrophosphate and/or alkali metal salts thereof in a cosmetic preparation comprising a) 2,4-bis{[4-(2 ethylhexyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine (INCI: Bis Ethylhexyloxyphenol Methoxyphenyl Triazine) when used to facilitate the washing out of UV photoprotective filters from textiles contaminated with the preparations.

It is advantageous in accordance with the invention if the preparation according to the invention comprises 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl) 1,3,5-triazine in an amount from 0.01 to 10% by weight, based on the total weight of the preparation.

It is preferred in accordance with the invention if the preparation according to the invention comprises 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine in an amount from 2 to 5% by weight, based on the total weight of the preparation.

It is advantageous in the context of the present invention if the preparation according to the invention comprises one or more complexing agents b) in an amount of 0.1 to 3% by weight, based on the total weight of the preparation.

It is preferred in the context of the present invention if the preparation according to the invention comprises one or more complexing agents b) in an amount of 0.5 to 1.5% by weight, based on the total weight of the preparation.

Embodiments of the present invention particularly preferred in accordance with the invention are characterized in that the complexing agents b) used are one or more of the compounds from the group comprising - diethylenetriaminepenta(methylenephosphonic acid)/ DTPMP - ethylenediaminetetra(methylenephosphonic acid/ EDTMP - aminotrimethylenephosphonic acid/ ATMP - sodium polyphosphate - tetrasodium pyrophosphate - succinic acid and/or alkali metal salts thereof.

O Advantageous alkali metal salts according to the invention are in this case sodium and potassium salts, sodium salts being preferred in accordance with the invention.

Embodiments of the present invention advantageous in accordance with the invention are characterized in that the ratio by weight of 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6 (4-methoxyphenyl)-1,3,5-triazine to the total amount of complexing agents of group b) is from 5:1 to 5:3.

It is advantageous in accordance with the invention if the preparation according to the invention is in the form of an emulsion. In accordance with the invention, it is preferred in such a case if the preparation is in the form of an oil-in-water emulsion (O/W emulsion).

In such a case, embodiments of the present invention advantageous in accordance with the invention are characterized in that the preparation comprises one or more emulsifiers selected from the group of compounds comprising glyceryl stearate citrate, cetearyl alcohol, sodium cetearyl sulfate, glyceryl stearate, cetearyl sulfosuccinate, sodium stearoyl glutamate, polyglyceryl-3 methylglucose distearate, polyglyceryl-3 methylglucose distearate, stearic acid, potassium cetyl phosphate.

It is advantageous in accordance with the invention if the preparation according to the invention comprises one or more UV filters selected from the group of compounds comprising 2-phenylbenzimidazole-5-sulfonic acid and/or salts thereof; phenylene-1,4-bis(2 benzimidazyl)-3,3'-5,5'-tetrasulfonic acid salts; 1,4-di(2-oxo-10-sulfo-3 bornylidenemethyl)benzene and salts thereof; 4-(2-oxo-3-bornylidenemethyl)benzenesulfonic acid salts; 2-methyl-5-(2-oxo-3-bornylidenemethyl)sulfonic acid salts; 2,2'-methylenebis(6 (2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol); 2-(2H-benzotriazo-2-yl)-4-methyl 6-[2-methyl-3-[1,3,3,3-tetramethyl-1-[(trimethylsilyl)oxy]disiloxanyl]propyl]phenol; 3-(4 methylbenzylidene)camphor; 3-benzylidenecamphor benzylidenecamphor; ethylhexyl salicylate; terephthalidenedicamphorsulfonic acid; 2-ethylhexyl 2-cyano-3,3-diphenylacrylate; 2-ethylhexyl 4-(dimethylamino)benzoate; amyl 4-(dimethylamino)benzoate; di(2-ethylhexyl) 4-methoxybenzalmalonate; 2-ethylhexyl 4-methoxycinnamate; isoamyl 4 methoxycinnamate; 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4' methylbenzophenone; 2,2'-dihydroxy-4-methoxybenzophenone; homomenthyl salicylate; 2 ethylhexyl 2-hydroxybenzoate; dimethicodiethylbenzalmalonate; 3-(4-(2,2-bis ethoxycarbonylvinyl)phenoxy)propenyl)methoxysiloxane / dimethylsiloxane - copolymer; hexyl 2-(4'-diethylamino-2'-hydoxybenzoyl)benzoate; dioctylbutylamidotriazone (INCI: Diethylhexyl Butamidotriazone); 2,4-bis[5-1(dimethylpropyl)benzoxazol-2-yl-(4-phenyl)imino] 6-(2-ethylhexyl)imino-1,3,5-triazine with (CAS No. 288254-16-0); 4-(tert-butyl)-4' methoxydibenzoylmethane; tris(2-ethylhexyl) 4,4',4"-(1,3,5-triazine-2,4,6 triyltriimino)trisbenzoate (also: 2,4,6-tris[anilino-(p-carbo-2'-ethyl-1'-hexyloxy)]-1,3,5-triazine (INCI: Ethylhexyl Triazone); 2,4,6-tribiphenyl-4-yl-1,3,5-triazine; merocyanine; titanium dioxide; zinc oxide.

It is particularly preferred in accordance with the invention in this case if the preparation is free of 3-(4-methylbenzylidene)camphor and 2-hydroxy-4-methoxybenzophenone (oxybenzone).

Advantageous embodiments according to the invention may be obtained wherein the preparation comprises ethylhexylglycerin, polyglyceryl-2 caprate, propylene glycol, butylene glycol, 2-methylpropane-1,3-diol, 1,2-pentanediol, 1,2-hexanediol, 1,2-octanediol and/or 1,2 decanediol.

It is advantageous in accordance with the invention if the preparation according to the invention comprises phenoxyethanol and/or methylparaben.

It is preferred in accordance with the invention in this case if the preparation is free of propylparaben and butylparaben, 3-iodo-2-propynyl butylcarbamate.

Advantageous embodiments in accordance with the invention are also characterized in that the emulsion comprises one or more active ingredients selected from the group of compounds comprising magnolia extract, gylcyrrhetic acid, urea, arctiin, alpha-lipoic acid, folic acid, phytoene, D-biotin, coenzyme Q10, alpha-glucosylrutin, carnitine, carnosine, caffeine, natural and/or synthetic isoflavonoids, glycerylglucose, creatine, creatinine, taurine, tocopherol, tocopherol acetate, p-alanine and/or licochalcone A.

The preparation according to the invention may further advantageously comprise glycerol and/or ethanol. In such a case, a glycerol concentration of 0.01 to 10% by weight, based on the total weight of the preparation, is advantageous in accordance with the invention. The range advantageous in accordance with the invention for ethanol is from 0.01 to 10% by weight, based on the total weight of the preparation.

The oil phase of the preparation according to the invention may also comprise further oil, fat or wax components, for example polar oils from the group of lecithins or compounds such as coco glyceride, capryl/capric triglyceride, olive oil, sunflower oil, jojoba oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, castor oil, wheatgerm oil, grapeseed oil, safflower oil, evening primrose oil, macadamia nut oil and so on. It is also possible to use compounds such as phenethyl benzoate, 2-phenylethyl benzoate, isopropyl lauroyl sarcosinate, phenyl trimethicone, cyclomethicone, dibutyl adipate, octyl palmitate, octyl cocoate, octyl isostearate, octyldodecyl myristate, octyldodecanol, cetearyl isononanoate, isopropyl myristate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononyl isononanoate, 2 ethylhexyl palmitate, 2-ethylhexyl laurate, 2-hexyldecyl stearate, 2-octyldodecyl palmitate, stearyl heptanoate, oleyl oleate, oleyl erucate, erucyl oleate, erucyl erucate, tridecyl stearate, tridecyl trimellitate.

Also advantageous in accordance with the invention are, for example, natural waxes of animal and vegetable origin such as beeswax and other insect waxes and berry wax, shea butter and/or lanolin (wool wax).

The oil phase may also be selected advantageously from the group of dialkyl ethers and dialkyl carbonates, e.g. dicaprylyl ether (Cetiol OE) and/or dicaprylyl carbonate, which may be obtained from Cognis for example under the trade name Cetiol CC, are advantageous.

It is also advantageous to select the oil component(s) from the group comprising isoeicosan, neopentyl glycol diheptanoate, propylene glycol dicaprylate/dicaprate, caprylic/capric/diglyceryl succinate, butylene glycol dicaprylate/dicaprate, C12-1 3 -alkyl lactate, di-C 12 - 13 -alkyl tartrate, triisostearin, dipentaerythrityl hexacaprylate/hexacaprate, propylene glycol monoisostearate, tricaprylin, dimethyl isosorbide. It is in particularly advantageous if the oil phase of the formulations according to the invention has a C12-1-alkyl benzoate content.

Advantageous oil components are also, e.g. isopropyl palmitate, myristyl myristate, butyloctyl salicylate (obtainable for example under the trade name Hal/brite BHB from CP Hall), tridecyl salicylate (which is obtainable under the trade name Cosmacol ESI from Sasol), C12-C15 alkyl salicylate (obtainable under the trade name Dermol NS from Alzo), hexadecyl benzoate and butyloctyl benzoate and mixtures thereof (HallstarAB).

Any mixtures of such oil and wax components can also be used advantageously in the context of the present invention.

The oil phase can also further comprise advantageously non-polar oils, for example those which can be selected from the group of branched and straight-chain hydrocarbons and waxes, especially mineral oil, vaseline (petrolatum), paraffin oil, squalane and squalene, polyolefins, hydrogenated polyisobutene, C13-16 isoparaffin and isohexadecane. In terms of polyolefins, the preferred substances are polydecenes.

Advantageous embodiments of the present invention in accordance with the invention are thereby also characterized in that the emulsion comprises dimethicone and/or cyclomethicone.

As polymeric film-forming agents for increasing water resistance, the preparation according to the invention can advantageously in accordance with the invention comprise vinylpyrrolidone/hexadecene. The addition of tapioca starch is also advantageous in accordance with the invention.

The preparation according to the invention can be used particularly advantageously as a daily care product or sunscreen.

Also in accordance with the invention is a method for facilitating the ability of cosmetic preparations comprising 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl) 1,3,5-triazine (INCI: Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine) to be washed out from textiles, characterized in that one or more complexing agents according to the invention are added to the cosmetic.

The method for reducing textile staining caused by cosmetic preparations comprising the UV photoprotective filter (especially 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(4 methoxyphenyl)-1,3,5-triazine) (INCI: Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine) is also in accordance with the invention, characterized in that one or more complexing agents according to the invention are added to the cosmetic.

Also in accordance with the invention is the use of complexing agents according to the invention in cosmetic preparations comprising 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl} 6-(4-methoxyphenyl)-1,3,5-triazine (INCI: Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine) for facilitating the ability of UV photoprotective filters to be washed out from textiles contaminated with the preparations, and also the use of complexing agents according to the invention in cosmetic preparations comprising UV photoprotective filters (especially 2,4 bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine (INCI: Bis Ethylhexyloxyphenol Methoxyphenyl Triazine)) for reducing textile staining caused by the preparation.

Comparative experiment

The effect in accordance with the invention can be substantiated with the following experiment by way of example: In each case, 1% auxiliary according to the invention was added to a formulation comprising Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine and the stain-reducing effect (reduction b*) compared to a formulation without complexing agent according to the invention was determined by the methods described.

As evidence of the improved ability to be washed out and reduced stain formation of the preparations according to the invention, in vitro investigations were conducted of which the results are presented in Figure 1 and Table 1. Various sunscreen emulsions were investigated with respect to the formation of yellow stains by means of an in vitro application/wash cycle. White pre-washed cotton monitors (100% cotton) were used here. For this purpose, 25 mg of the test formulation were distributed uniformly on PMMA Sch6nberg plates (5.0 x 5.0 cm) and transferred directly to the test textile by pressure. The stained cotton samples were then dried in air under laboratory conditions for 12 h. After drying, a colorimetric characterization of the resulting initial staining is carried out by measuring the degree of yellowing using the color measuring instrument spectro-color (Dr. Lange); color measurement software: spectral-QC, version measurement geometry: d/80

, gloss component excluded, type of light: D65 (corresponding to average daylight), calibration standard: LZM 268, measurement aperture: 10mm, sample background: substrate paper without optical brightener, test climate: 21C (±10C), 41% (±4%)rel. atmospheric humidity. For the evaluation, the changes in the b value from the CIE-Lab color measurement system are used. The B axis in the CIE-Lab system characterizes the yellow/blue color impression, where positive b values stand for an increase in the yellow fraction. The higher the b value, the greater the yellow impression. After the measurement procedure, a separate washing of the test cloths is carried out in the dye- and washing-fastness device Linitest Plus (Atlas) (600C, 1 h, 20 rpm, Ariel Compact powder detergent, 10 metal balls as ballast) and then a rinsing procedure (20°C, 15 min, tap water). After drying for 12 h under laboratory conditions, a colorimetric colorization of the resulting staining is carried out again by measuring the color values as already described using the spectro-color colorimeter (Dr. Lange).

The CIE-Lab system or L*a*b* color space is a three-dimensional measurement space in which all perceivable colors are contained. The color space is constructed on the basis of the opponent color theory. One of the most important properties of the L*a*b* color model is its instrument independence, i.e. the colors are defined independently of the nature of their production and display technology. The corresponding EU guideline is DIN EN ISO 11664-4 "Colorimetry - part 4: CIE 1976 L*a*b* color space". The coordinates of the CIELAB plane are formed from the red/green value a and the yellow/blue value b. The lightness axis L stands perpendicular to this plane. According to DIN 6174, L, a and b should be written with * in order to differentiate them from others, e.g. the "Hunter-Lab" system.

Table 1: Preparations tested and their yellow value reduction of stains; b* value[%]

INCI Ex. 1 Ex. 2 Ex. 3 Ex. 4 Ex. 5 Ex. 6 Ex. 7 Potassium Trisphosphonomethylamine Oxide 1.0 Sodium polyphosphate 1.0 Tetrasodium pyrophosphate 1.0 Sodium diethylenetriaminepentamethylenephosphonate 1.0 Sodium EDTMP 1.0 Diethylenetriaminepentamethylenephosphonic 1.0 acid/hydrochloric acid Caprylic/Capric Triglycerides 4.0 4.0 4.0 4.0 4.0 4.0 4.0 Glyceryl Stearate 1.0 1.0 1.0 1.0 1.0 1.0 1.0 Hydrogenated Coco-Glycerides 1.0 1.0 1.0 1.0 1.0 1.0 1.0 Sodium Stearoyl Glutamate 0.3 0.3 0.3 0.3 0.3 0.3 0.3 Silica Dimethyl Silylate 0.3 0.3 0.3 0.3 0.3 0.3 0.3 Tapioca starch 1.0 1.0 1.0 1.0 1.0 1.0 1.0 Perfume 0.5 0.5 0.5 0.5 0.5 0.5 0.5 Glycerol 0.9 0.9 0.9 0.9 0.9 0.9 0.9 Phenoxyethanol 0.6 0.6 0.6 0.6 0.6 0.6 0.6 Methylparaben 0.3 0.3 0.3 0.3 0.3 0.3 0.3 Acrylates/C10-30 Alkyl Acrylate Crosspolymer 0.15 0.15 0.15 0.15 0.15 0.15 0.15 Xanthan Gum 0.4 0.4 0.4 0.4 0.4 0.4 0.4 Alcohol Denat. 8.0 8.0 8.0 8.0 8.0 8.0 8.0 Trissodium EDTA 0.2 0.2 0.2 0.2 0.2 0.2 0.2 Octocrylene 9.0 9.0 9.0 9.0 9.0 9.0 9.0 Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine 3.0 3.0 3.0 3.0 3.0 3.0 3.0

Water to to to to to to to 100 100 100 100 100 100 100

Reduction b* [%] -31 -45 -23 -87 -84 -85 0

The results show a clear stain reduction by using complexing agents compared to the formulation without the complexing agents according to the invention (example 7).

Examples

The examples are intended to illustrate the invention without limiting it. Unless otherwise stated, all quantitative data, fractions and percentages are based on the weight and on the total amount or the total weight of the preparations.

INCI Example[%] 8 9 10 11 12 Potassium Trisphosphonomethylamine Oxide 0.50 0.50 Sodium polyphosphate 0.50 Tetrasodium Pyrophosphate 0.50 Sodium 0.50 0.50 diethylenetriaminepentamethylenephosphonate Sodium EDTMP 0.50 Diethylenetriaminepentamethylenephosphonic 0.50 acid/hydrochloric acid Trisodium EDTA 0.20 0.50 0.50 0.20 0.50 Butyl methoxydibenzoylmethane 5.00 3.00 3.00 5.00 4.50 Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine 3.50 3.50 5.50 5.50 3.50 Phenylbenzimidazole Sulfonic Acid 1.00 1.00 1.00 1.00 Ethylhexyl Salicylate 5.00 5.00 5.00 Titanium Dioxide 3.00 2.00 3.00 Trimethoxycaprylylsilane 0.20 0.20 0.20 Octocrylene 10.00 10.00 10.00 10.00 9.00 Homosalate 10.00 10.00 10.00 9.50 Cetearyl Alcohol 1.00 0.50 Xanthan Gum 0.40 0.40 0.40 0.40 Acrylates/C10-30 Alkyl Acrylate Crosspolymer 0.30 0.05 0.20 0.40 0.30 Alcohol Denat. 5.00 4.00 6.00 6.00 5.00 Methylparaben 0.30 0.30 0.30 0.30 0.30 Phenoxyethanol 0.60 0.60 0.60 0.60 0.60 Citric Acid 0.30 0.30 Sodium Citrate 0.10 0.10 Glycerol 3.00 9.00 3.00 9.00 3.00 Perfume 0.40 0.60 0.30 VP/Hexadecene Copolymer 0.50 0.50 0.50 0.50 Silica Dimethyl Silylate 0.50 0.50 Sodium Cetearyl Sulfate 0.15 Glyceryl Stearate SE 1.00 Glyceryl Stearate Citrate 2.00 2.00 Ceteareth-20 1.00 Sodium Stearoyl Glutamate 0.40 Glyceryl Stearate 1.00 Hydrogenated Coco-Glycerides 1.00 1.00 1.00 C12-15 Alkyl Benzoate 5.00 5.00 Myristyl Myristate 1.00 1.00 1.00

Stearyl Alcohol 0.50 0.50 C18-36 Acid Triglyceride 0.50 C18-38 Alkyl Hydroxystearoyl Stearate 0.50 Isopropyl Stearate 2.00 2.00 Butylene Glycol Dicaprylate/Dicaprate 5.00 3.00 5.00 Aqua to 100 to 100 to 100 to 100 to 100

Claims

Patent claims 1. A cosmetic preparation comprising a) 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine (INCI: Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine);and b) one or more complexing agents selected from the group consisting of - 1-hydroxyethane-(1,1-diphosphonic acid)/ HEDP - aminotrimethylenephosphonic acid/ ATMP - diethylenetriaminepenta(methylenephosphonic acid)/ DTPMP - phosphonobutanetricarboxylic acid/ PBTC - tetrasodium pyrophosphate and/or alkali metal salts thereof.
2. The cosmetic preparation as claimed in claim 1, wherein the preparation comprises a) 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl)-1,3,5-triazine (INCI: Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine) in an amount from 0.01 to 10.0% by weight, based on the total weight of the preparation.
3. The cosmetic preparation as claimed in either of the preceding claims, wherein the preparation comprises one or more complexing agents b) in a total amount of 0.1 to 3% by weight, based on the total weight of the preparation.
4. The cosmetic preparation as claimed in any of the preceding claims, wherein the ratio by weight of a) 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(4-methoxyphenyl) 1,3,5-triazine (INCI: Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine) to the total amount of complexing agents of group b) is from 5:1 to 5:3.
5. The cosmetic preparation as claimed in any of the preceding claims, wherein the complexing agent b) used is one or more compounds from the group consisting of - aminotrimethylenephosphonic acid/ ATMP - diethylenetriaminepenta(methylenephosphonic acid)/ DTPMP - tetrasodium pyrophosphate and/or alkali metal salts thereof.
6. The cosmetic preparation as claimed in any of the preceding claims, wherein the preparation is in the form of an oil-in-water emulsion (01Wemulsion).
7. The cosmetic preparation as claimed in any of the preceding claims, wherein the preparation comprises one or more emulsifiers selected from the group of compounds consisting of glyceryl stearate citrate, cetearyl alcohol, sodium cetearyl sulfate + glyceryl stearate, cetearyl sulfosuccinate, sodium stearoyl glutamate, polyglyceryl-3 methylglucose distearate, polyglyceryl-3 methylglucose distearate, stearic acid, potassium cetyl phosphate.
8. The cosmetic preparation as claimed in any of the preceding claims, wherein the preparation comprises one or more UV filters selected from the group of compounds consisting of 2-phenylbenzimidazole-5-sulfonic acid and/or salts thereof; phenylene 1,4-bis(2-benzimidazyl)-3,3'-5,5'-tetrasulfonic acid salts; 1,4-di(2-oxo-10-sulfo-3 bornylidenemethyl)benzene and salts thereof; 4-(2-oxo-3 bornylidenemethyl)benzenesulfonic acid salts; 2-methyl-5-(2-oxo-3 bornylidenemethyl)sulfonic acid salts; 2,2'-methylenebis(6-(2H-benzotriazo-2-yl)-4 (1,1,3,3-tetramethylbutyl)phenol); 2-(2H-benzotriazol-2-yl)-4-methyl-6-[2-methyl-3

[1,3,3,3-tetramethyl-1-[(trimethylsilyl)oxy]disiloxanyl]propyl]phenol; 3-(4 methylbenzylidene)camphor; 3-benzylidenecamphor; ethylhexyl salicylate; terephthalidenedicamphorsulfonic acid; 2-ethylhexyl 2-cyano-3,3-diphenylacrylate; 2 ethylhexyl 4-(dimethylamino)benzoate; amyl 4-(dimethylamino)benzoate; di(2 ethylhexyl) 4-methoxybenzalmalonate; 2-ethylhexyl 4-methoxycinnamate; isoamyl 4 methoxycinnamate; 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4' methylbenzophenone; 2,2'-dihydroxy-4-methoxybenzophenone; homomenthyl salicylate; 2-ethylhexyl 2-hydroxybenzoate; dimethicodiethylbenzalmalonate; 3-(4 (2,2-bis ethoxycarbonylvinyl)phenoxy)propenyl)methoxysiloxane / dimethylsiloxane copolymer; hexyl 2-(4'-diethylamino-2'-hydoxybenzoyl)benzoate; dioctylbutylamidotriazone (INCI: Diethylhexyl Butamidotriazone); 2,4-bis[5 1(dimethylpropyl)benzoxazol-2-yl-(4-phenyl)imino]-6-(2-ethylhexyl)imino-1,3,5-triazine with (CAS No. 288254-16-0); 2,4-bis{[4-(2-ethylhexyloxy)-2-hydroxy]phenyl}-6-(4 methoxyphenyl)-1,3,5-triazine (INCI: Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine); 4-(tert-butyl)-4'-methoxydibenzoylmethane; tris(2-ethylhexyl) 4,4',4"-(1,3,5 triazine-2,4,6-triyltriimino)trisbenzoate (also: 2,4,6-tris[anilino-(p-carbo-2'-ethyl-1' hexyloxy)]-1,3,5-triazine (INCI: Ethylhexyl Triazone); 2,4,6-tribiphenyl-4-yl-1,3,5 triazine; merocyanine; titanium dioxide; zinc oxide.
9. The cosmetic preparation as claimed in any one of the preceding claims, wherein the preparation comprises one or more compounds selected from the group of compounds consisting of ethylhexylglycerin, polyglyceryl-2 caprate, propylene glycol, butylene glycol, 2-methylpropane-1,3-diol, 1,2-pentanediol, 1,2-hexanediol, 1,2 octanediol and/or 1,2-decanediol.
10. The cosmetic preparation as claimed in any one of the preceding claims, wherein the preparation comprises phenoxyethanol and/or methylparaben.
11. The cosmetic preparation as claimed in any one of the preceding claims, wherein the emulsion comprises one or more active ingredients selected from the group of compounds consisting of magnolia extract, gylcyrrhetic acid, urea, arctiin, alpha-lipoic acid, folic acid, phytoene, D-biotin, coenzyme Q10, alpha-glucosylrutin, carnitine, carnosine, caffeine, natural and/or synthetic isoflavonoids, glycerylglucose, creatine, creatinine, taurine, tocopherol, tocopherol acetate, p-alanine and/or licochalcone A.